There are nearly 125 000 patients receiving vascular endothelial growth factor (VEGF) injections in the USA as of 2015, and a large subset of these patients are vulnerable, and at risk for worsening renal function, proteinuria and end-stage renal disease [6, 7]. Here, VEGFA is linked to chronic kidney disease.